Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Fig. 4

Mean changes from baseline in total PsA-modified SHS by CDAI-defined disease activity state. Results are shown at week 24 (a) and week 52 (b). CDAI, Clinical Disease Activity Index; HDA, high disease activity; IV, intravenous; LDA, low disease activity; ModDA, moderate disease activity; PsA, psoriatic arthritis; SD, standard deviation; SHS, – Sharp/van der Heijde score

Back to article page
\